CNA Financial Corp purchased a new stake in Allergan PLC. (NYSE:AGN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 12,670 shares of the company’s stock, valued at approximately $2,597,000.

Several other institutional investors and hedge funds also recently bought and sold shares of AGN. Howard Hughes Medical Institute acquired a new stake in shares of Allergan PLC. in the 2nd quarter valued at approximately $103,000. Cable Hill Partners LLC boosted its stake in shares of Allergan PLC. by 255.2% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after purchasing an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. boosted its stake in shares of Allergan PLC. by 283.7% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after purchasing an additional 400 shares in the last quarter. Jacobi Capital Management LLC boosted its stake in shares of Allergan PLC. by 4.9% in the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares in the last quarter. Finally, Massey Quick & Co. LLC boosted its stake in shares of Allergan PLC. by 334.8% in the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares in the last quarter. Institutional investors own 81.21% of the company’s stock.

Allergan PLC. (NYSE AGN) traded up $1.77 on Wednesday, reaching $173.59. 1,526,850 shares of the company’s stock were exchanged, compared to its average volume of 2,913,987. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. The stock has a market cap of $57,140.00, a P/E ratio of 11.31, a price-to-earnings-growth ratio of 1.11 and a beta of 1.12. Allergan PLC. has a 1 year low of $169.61 and a 1 year high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.32 EPS. sell-side analysts forecast that Allergan PLC. will post 16.28 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.61%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan PLC.’s dividend payout ratio is -12.39%.

Allergan PLC. declared that its Board of Directors has authorized a share buyback program on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This news story was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://theolympiareport.com/2017/11/15/cna-financial-corp-purchases-new-position-in-allergan-plc-agn.html.

Several equities research analysts recently commented on the stock. Mizuho reiterated a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Wells Fargo & Company lifted their target price on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a research report on Thursday, August 3rd. Credit Suisse Group reiterated an “outperform” rating and set a $286.00 target price (up from $274.00) on shares of Allergan PLC. in a research report on Thursday, July 20th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $278.00 target price (up from $273.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $246.73.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.